Potential of a <scp>glucagon‐like peptide‐1 receptor</scp> /glucose‐dependent insulinotropic polypeptide receptor/ <scp>glucagon receptor</scp> triagonist for the treatment of obesity and type 2 diabetes-Reference-Cited by-同舟云学术

Potential of a glucagon‐like peptide‐1 receptor /glucose‐dependent insulinotropic polypeptide receptor/ glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

Published:2022-08-30 Issue:12 Volume:13 Page:1958-1960
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J of Diabetes Invest

Author:

Araki Eiichi¹²^ORCID,Sakaguchi Masaji¹,Fukuda Kazuki¹²,Kondo Tatsuya¹^ORCID

Affiliation:

1. Department of Metabolic Medicine Faculty of Life Sciences Kumamoto University Kumamoto Japan

2. Center for Metabolic Regulation of Healthy Aging Faculty of Life Sciences Kumamoto University Kumamoto Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13896

Reference9 articles.

1. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

2. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

3. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

4. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

5. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on peptide-based therapies for type 2 diabetes and obesity;Peptides;2023-03